Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Buy
51
XBI Quote, Financials, Valuation and Earnings
Last price:
$78.78
Seasonality move
:
5.33%
Day range:
$78.70 - $79.98
52-week range:
$66.66 - $105.47
Dividend yield:
0.17%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
15.2M
Avg. volume:
12M
1-year change:
-10.73%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
$79.30 | -- | -- | -- | $0.01 | 0.17% | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
$62.49 | -- | -- | -- | $0.25 | 1.6% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$62.97 | -- | -- | -- | $0.03 | 0.07% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$79.84 | -- | -- | -- | $0.27 | 1.14% | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
$132.16 | -- | -- | -- | $0.56 | 1.77% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$40.17 | -- | -- | -- | $0.15 | 1.64% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.543 | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | 0.959 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.183 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.581 | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | 0.887 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.578 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
FHLC
Fidelity MSCI Health Care Index ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XLV
Health Care Select Sector SPDR Fund
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Biotech ETF vs. Competitors
-
Which has Higher Returns XBI or FHLC?
Fidelity MSCI Health Care Index ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Fidelity MSCI Health Care Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- -
What do Analysts Say About XBI or FHLC?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Fidelity MSCI Health Care Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Fidelity MSCI Health Care Index ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Fidelity MSCI Health Care Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 FHLCFidelity MSCI Health Care Index ETF0 0 0 -
Is XBI or FHLC More Risky?
SPDR S&P Biotech ETF has a beta of 0.976, which suggesting that the stock is 2.396% less volatile than S&P 500. In comparison Fidelity MSCI Health Care Index ETF has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.843%.
-
Which is a Better Dividend Stock XBI or FHLC?
SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.17%. Fidelity MSCI Health Care Index ETF offers a yield of 1.6% to investors and pays a quarterly dividend of $0.25 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Fidelity MSCI Health Care Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or FHLC?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Fidelity MSCI Health Care Index ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Fidelity MSCI Health Care Index ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Fidelity MSCI Health Care Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Fidelity MSCI Health Care Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- FHLCFidelity MSCI Health Care Index ETF-- -- -- --
-
Which has Higher Returns XBI or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XBI or PBE?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XBI or PBE More Risky?
SPDR S&P Biotech ETF has a beta of 0.976, which suggesting that the stock is 2.396% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.98%.
-
Which is a Better Dividend Stock XBI or PBE?
SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.17%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PBE?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XBI or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XBI or PJP?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XBI or PJP More Risky?
SPDR S&P Biotech ETF has a beta of 0.976, which suggesting that the stock is 2.396% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.530, suggesting its less volatile than the S&P 500 by 46.992%.
-
Which is a Better Dividend Stock XBI or PJP?
SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.17%. Invesco Pharmaceuticals ETF offers a yield of 1.14% to investors and pays a quarterly dividend of $0.27 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PJP?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XBI or XLV?
Health Care Select Sector SPDR Fund has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Health Care Select Sector SPDR Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- XLVHealth Care Select Sector SPDR Fund-- -- -- -
What do Analysts Say About XBI or XLV?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Health Care Select Sector SPDR Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Health Care Select Sector SPDR Fund, analysts believe SPDR S&P Biotech ETF is more attractive than Health Care Select Sector SPDR Fund.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 XLVHealth Care Select Sector SPDR Fund0 0 0 -
Is XBI or XLV More Risky?
SPDR S&P Biotech ETF has a beta of 0.976, which suggesting that the stock is 2.396% less volatile than S&P 500. In comparison Health Care Select Sector SPDR Fund has a beta of 0.691, suggesting its less volatile than the S&P 500 by 30.908%.
-
Which is a Better Dividend Stock XBI or XLV?
SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.17%. Health Care Select Sector SPDR Fund offers a yield of 1.77% to investors and pays a quarterly dividend of $0.56 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Health Care Select Sector SPDR Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XLV?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Health Care Select Sector SPDR Fund quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Health Care Select Sector SPDR Fund's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Health Care Select Sector SPDR Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Health Care Select Sector SPDR Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- XLVHealth Care Select Sector SPDR Fund-- -- -- --
-
Which has Higher Returns XBI or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XBI or XPH?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe SPDR S&P Biotech ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is XBI or XPH More Risky?
SPDR S&P Biotech ETF has a beta of 0.976, which suggesting that the stock is 2.396% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.443%.
-
Which is a Better Dividend Stock XBI or XPH?
SPDR S&P Biotech ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.17%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.64% to investors and pays a quarterly dividend of $0.15 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or XPH?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Apple Stock Undervalued or Overvalued?
For many years, Apple (NASDAQ:AAPL) was just about the perfect…
Where Will Palo Alto Networks Stock Be in 5 Years?
You know those companies that just refuse to slow down…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
TNXP alert for May 28
Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.
Buy
70
AGFY alert for May 29
Agrify [AGFY] is up 18.95% over the past day.
Buy
88
SMR alert for May 28
NuScale Power [SMR] is down 0.37% over the past day.
